Bristol Myers Squibb (BMY) Total Non-Current Liabilities (2009 - 2026)

Bristol Myers Squibb has disclosed Total Non-Current Liabilities across 18 years of filings, most recently posting $61.5 billion for Q1 2026.

• In Q1 2026, Total Non-Current Liabilities fell 12.74% year-over-year to $61.5 billion; the TTM figure through Mar 2026 stood at $61.5 billion (down 12.74% YoY), while the FY2025 annual figure was $66.5 billion, down 7.33% from the prior year.
• Total Non-Current Liabilities fell to $61.5 billion in Q1 2026, from $66.5 billion in the prior quarter.
• Over the last five years, Total Non-Current Liabilities for BMY reached as high as $75.8 billion in Q1 2024 and fell as low as $55.6 billion in Q2 2023.
• The 5-year median for Total Non-Current Liabilities is $64.1 billion (2022), against an average of $65.0 billion.
• Annual changes were most pronounced in 2023 — Total Non-Current Liabilities dropped 13.03% — and 2024, when it soared 35.92%.
• A 5-year view of Total Non-Current Liabilities shows it stood at $59.1 billion in 2022, then increased by 0.24% to $59.3 billion in 2023, then advanced by 21.08% to $71.7 billion in 2024, then dropped by 7.33% to $66.5 billion in 2025, then decreased by 7.47% to $61.5 billion in 2026.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $61.5 billion, $66.5 billion, and $72.8 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.